<DOC>
	<DOC>NCT01242176</DOC>
	<brief_summary>The objective of the study is to investigate the relative bioavailability of the final tablet formulation (FF) of BI 10773 in comparison to the tablet formulation 2 (TF2).</brief_summary>
	<brief_title>Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: Healthy male and female subjects</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>